Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Design Therapeutics, Inc.NASDAQ: DSGN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $5.33M rose 5.7% year over year, behind the +11.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 12.3% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +12.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.33M+12.3% QoQ
- Last fiscal yearDec 2025
- $20.34M+12.8% YoY
- LTMMar 2026
- $20.62M+11.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.7% | -100.0% | -105.7 pp |
| 1 year | +12.8% | -100.0% | -112.8 pp |
| 3-year CAGR | +2.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.34M USD
- Year-over-year change
- +12.8%
- 4-year CAGR
- +16.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.34M | +12.8% |
| FY2024 | 2024-12-31 | 18.03M | -14.6% |
| FY2023 | 2023-12-31 | 21.13M | +11.3% |
| FY2022 | 2022-12-31 | 18.98M | +71.7% |
| FY2021 | 2021-12-31 | 11.05M | — |
Selling, General & Admin vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 selling, general & admin of $20.62M is the 10th highest of the 11 companies compared; the peer median is $75.14M.
- Its year-over-year change of +11.6% is the 6th highest of 11, against a peer median of +13.5%.
- Over three fiscal years its annual growth of +2.3% compares with a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Mar 2026 | $467.04M | -17.3% | +2.0% | 21.4% | |
| LTM Jun 2026 | $351.33M | +8.3% | +2.1% | 34.8% | |
| LTM Jun 2026 | $91.25M | +50.5% | +35.3% | — | |
| LTM Mar 2026 | $79.08M | +23.9% | +14.3% | 110.1% | |
| LTM Mar 2026 | $71.21M | +35.2% | +19.9% | 222.0% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $29.77M | -10.8% | -11.7% | — | |
| LTM Mar 2026 | $22.56M | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $20.62M | +11.6% | +2.3% | — | |
| LTM Mar 2026 | $19.82M | +7.4% | +14.2% | — | |
| Peer median (excluding DSGN) | $75.14M | +13.5% | +14.2% | 61.0% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.